MINI FUTURE LONG - POLE GROU Stock

DE000MG06915

Market Closed - Börse Stuttgart 08:47:09 2024-07-08 EDT
1.63 ^EUR	+2.52%

Current month	+13.99%
1 month	-7.91%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart POLYPEPTIDE GROUP AG

Latest news about POLYPEPTIDE GROUP AG

PolyPeptide : and Donaldson collaborate to develop solvent recovery system for peptide purification	05-13	PU
Donaldson Company, Inc. and PolyPeptide Group AG Partners to Improve Sustainability in Peptide Manufacturing with Solvent Recovery Technology	05-13	CI
Hamlet BioPharma secures large scale Alpha1 peptide production in an agreement with Polypeptide Group	04-18	AQ
PolyPeptide announces results of the annual General Meeting 2024	04-10	EQ

More news

Quotes 5-day view

Date	Price	Change
24-07-08	1.63	+2.52%
24-07-05	1.59	+8.90%
24-07-04	1.46	+6.57%
24-07-03	1.37	-0.72%
24-07-02	1.38	0.00%

Delayed Quote Börse Stuttgart

Last update July 08, 2024 at 08:47 am

More quotes

Static data

Product type	Certificat Turbo Stop Loss
Buy / Sell	CALL
Underlying	POLYPEPTIDE GROUP AG
Issuer	Morgan Stanley
WKN	MG0691
ISIN	DE000MG06915
Date issued	2024-03-13
Strike	15.56 CHF
Maturity	Unlimited
Parity	10 : 1
Emission price	0.28 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.9 €
Lowest since issue	0.53 €

Company Profile

Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.

Sector

More about the company

Ratings for PolyPeptide Group AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: PolyPeptide Group AG

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

32.2 EUR

Average target price

26.74 EUR

Spread / Average Target

-16.98%

Consensus